Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system

M Trojani, G Contesso, Jean‐Michel Coindre, +7

International Journal of Cancer

Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group.

J.M. Coindre, Philippe Terrier, N.B. Bui, +12

Journal of Clinical Oncology

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)

Stéphane Culine, Pierre Kerbrat, A. Kramar, +11

Annals of Oncology

UrologySurgical OncologyCancer CentersGenitourinary CancerMedicine +6

Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study.

I. L. Ray-Coquard, N.B. Bui, Antoine Adenis, +6

Journal of Clinical Oncology

Surgical OncologyDisease ProgressionPrognosisPathologyLogistic Analysis +20

Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials

Alain Ravaud, N.B. Bui, Coindre Jm, +8

British Journal of Cancer

Surgical OncologyPrognostic VariablesMedicineCancer ManagementPathology +5

Pharmacokinetics of doxorubicin in sarcoma patients

Jacques Robert, N.B. Bui, Patricia Vrignaud

European Journal of Clinical Pharmacology

OncologyMedicinePharmacotherapySarcoma PatientsPharmacology +2

Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3.

Peter Reichardt, Jean‐Yves Blay, Hans Gelderblom, +7

Journal of Clinical Oncology

Original article: Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma

Jacques Robert, N.B. Bui

Annals of Oncology

MedicineMetronomic TherapyPharmacologyAdvanced Soft-tissue SarcomaPharmacotherapy +5

Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052).

Patrick Schöffski, I. L. Ray-Coquard, Angela Cioffi, +7

Journal of Clinical Oncology

Tumor BiologyBone Sarcoma GroupSoft Tissue SarcomaMalignant DiseaseMedicine +13

Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial.

Jean‐Yves Blay, A. Le Cesne, N.B. Bui, +6

Journal of Clinical Oncology

Surgical OncologyPathologyPharmacotherapyMetronomic ChemotherapyTumor Biology +21